$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[해외논문] Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia 원문보기

Cell, v.173 no.6, 2018년, pp.1439 - 1453.e19  

Kim, Miriam Y. (Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine) ,  Yu, Kyung-Rok (Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health) ,  Kenderian, Saad S. (Division of Hematology, Mayo Clinic) ,  Ruella, Marco (Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine) ,  Chen, Shirley (Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health) ,  Shin, Tae-Hoon (Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health) ,  Aljanahi, Aisha A. (Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health) ,  Schreeder, Daniel (Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania School of Medicine) ,  Klichinsky, Michael (Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine) ,  Shestova, Olga (Center for Cellular) ,  Kozlowski, Miroslaw S. ,  Cummins, Katherine D. ,  Shan, Xinhe ,  Shestov, Maksim ,  Bagg, Adam ,  Morrissette, Jennifer J.D. ,  Sekhri, Palak ,  Lazzarotto, Cicera R. ,  Calvo, Katherine R. ,  Kuhns, Douglas B. ,  Donahue, Robert E. ,  Behbehani, Gregory K. ,  Tsai, Shengdar Q. ,  Dunbar, Cynthia E. ,  Gill, Saar

Abstract AI-Helper 아이콘AI-Helper

Summary The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal mye...

주제어

참고문헌 (54)

  1. Blood Appelbaum 130 2373 2017 10.1182/blood-2017-09-797712 Gemtuzumab ozogamicin for acute myeloid leukemia 

  2. Cancer Discov. Behbehani 5 988 2015 10.1158/2159-8290.CD-15-0298 Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy 

  3. Cell Stem Cell Biasco 19 107 2016 10.1016/j.stem.2016.04.016 In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases 

  4. Nucleic Acids Res. Brinkman 42 e160 2014 10.1093/nar/gku936 Easy quantitative assessment of genome editing by sequence trace decomposition 

  5. Mol. Cell. Biol. Brinkman-Van der Linden 23 4199 2003 10.1128/MCB.23.12.4199-4206.2003 CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice 

  6. Immunology Cao 132 18 2011 10.1111/j.1365-2567.2010.03368.x Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? 

  7. Science Cong 339 819 2013 10.1126/science.1231143 Multiplex genome engineering using CRISPR/Cas systems 

  8. Sci. Transl. Med. Davila 6 224ra25 2014 10.1126/scitranslmed.3008226 Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia 

  9. Nat. Biotechnol. Doench 32 1262 2014 10.1038/nbt.3026 Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation 

  10. Donahue Chapter 22 2005 Large animal models for stem and progenitor cell analysis. Curr. Protoc. Immunol 

  11. Adv. Hematol. Dutour 2012 683065 2012 10.1155/2012/683065 In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia 

  12. Cytometry A Finck 83 483 2013 10.1002/cyto.a.22271 Normalization of mass cytometry data with bead standards 

  13. Nat. Biotechnol. Fu 32 279 2014 10.1038/nbt.2808 Improving CRISPR-Cas nuclease specificity using truncated guide RNAs 

  14. Nature Genovese 510 235 2014 10.1038/nature13420 Targeted genome editing in human repopulating haematopoietic stem cells 

  15. Blood Gill 123 2343 2014 10.1182/blood-2013-09-529537 Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells 

  16. Nat. Biotechnol Hsu 31 827 2013 10.1038/nbt.2647 DNA targeting specificity of RNA-guided Cas9 nucleases 

  17. J. Biol. Chem. Ishida 289 25341 2014 10.1074/jbc.M113.523480 Negative regulation of Toll-like receptor-4 signaling through the binding of glycosylphosphatidylinositol-anchored glycoprotein, CD14, with the sialic acid-binding lectin, CD33 

  18. Leukemia Kenderian 29 1637 2015 10.1038/leu.2015.52 CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia 

  19. J. Clin. Oncol. Kochenderfer 33 540 2015 10.1200/JCO.2014.56.2025 Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor 

  20. Curr. Protoc. Cytom. Kotecha Chapter 10 2010 Web-based analysis and publication of flow cytometry experiments 

  21. Blood Rev. Laszlo 28 143 2014 10.1016/j.blre.2014.04.001 The past and future of CD33 as therapeutic target in acute myeloid leukemia 

  22. Lancet Lee 385 517 2015 10.1016/S0140-6736(14)61403-3 T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial 

  23. Nature Lek 536 285 2016 10.1038/nature19057 Analysis of protein-coding genetic variation in 60,706 humans 

  24. Blood Leong 129 609 2017 10.1182/blood-2016-08-735365 An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia 

  25. Cell Levine 162 184 2015 10.1016/j.cell.2015.05.047 Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis 

  26. Blood Mardiros 122 3138 2013 10.1182/blood-2012-12-474056 T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia 

  27. N. Engl. J. Med. Maude 371 1507 2014 10.1056/NEJMoa1407222 Chimeric antigen receptor T cells for sustained remissions in leukemia 

  28. Mol. Ther. Milone 17 1453 2009 10.1038/mt.2009.83 Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo 

  29. Science Narasimhan 352 474 2016 10.1126/science.aac8624 Health and population effects of rare gene knockouts in adult humans with related parents 

  30. Exp. Hematol. Nguyen 34 728 2006 10.1016/j.exphem.2006.03.003 Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs 

  31. Science Notta 333 218 2011 10.1126/science.1201219 Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment 

  32. J. Anal. At. Spectrom. Ornatsky 23 463 2008 10.1039/b710510j Development of analytical methods for multiplex bio-assay with inductively coupled plasma mass spectrometry 

  33. Blood Paul 96 483 2000 10.1182/blood.V96.2.483.014k40_483_490 Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2 

  34. Blood Peterson 127 2416 2016 10.1182/blood-2015-09-672337 Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates 

  35. Biotechnol Pinello 34 695 2016 Analyzing CRISPR genome-editing experiments with CRISPResso. Nat 

  36. Leukemia Pizzitola 28 1596 2014 10.1038/leu.2014.62 Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo 

  37. Nat. Biotechnol. Qiu 29 886 2011 10.1038/nbt.1991 Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE 

  38. Nature Saleheen 544 235 2017 10.1038/nature22034 Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity 

  39. Nat. Med. Scott 23 1095 2017 10.1038/nm.4377 Implications of human genetic variation in CRISPR-based therapeutic genome editing 

  40. Nat. Methods Shen 11 399 2014 10.1038/nmeth.2857 Efficient gnome modification by CRISPR-Cas9 nickase with minimal off-target effects 

  41. Cancer Discov. Sotillo 5 1282 2015 10.1158/2159-8290.CD-15-1020 Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy 

  42. PLoS One Stemmer 10 e0124633 2015 10.1371/journal.pone.0124633 CCTop: An Intuitive, Flexible and Reliable CRISPR/Cas9 Target Prediction Tool 

  43. Nat. Genet. Sulem 47 448 2015 10.1038/ng.3243 Identification of a large set of rare complete human knockouts 

  44. Mol. Ther. Tashiro 25 2202 2017 10.1016/j.ymthe.2017.05.024 Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1 

  45. Blood Taussig 106 4086 2005 10.1182/blood-2005-03-1072 Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia 

  46. J. Biol. Chem. Taylor 274 11505 1999 10.1074/jbc.274.17.11505 The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2 

  47. Nat. Methods Tsai 14 607 2017 10.1038/nmeth.4278 CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets 

  48. J. Clin. Invest. Turtle 126 2123 2016 10.1172/JCI85309 CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients 

  49. Eur. J. Immunol. Ulyanova 29 3440 1999 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.0.CO;2-C The sialoadhesin CD33 is a myeloid-specific inhibitory receptor 

  50. Mol. Ther. Wang 23 184 2015 10.1038/mt.2014.164 Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia 

  51. Cell Stem Cell Wu 14 486 2014 10.1016/j.stem.2014.01.020 Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage origin for natural killer cells 

  52. J. Exp. Med. Wu 215 217 2018 10.1084/jem.20171341 Geographic clonal tracking in macaques provides insights into HSPC migration and differentiation 

  53. Nat. Commun. Yang 5 5507 2014 10.1038/ncomms6507 Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells 

  54. Protoc Zunder 10 316 2015 10.1038/nprot.2015.020 Nat 

LOADING...

관련 콘텐츠

오픈액세스(OA) 유형

BRONZE

출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문

이 논문과 함께 이용한 콘텐츠

유발과제정보 저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로